TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23761205
Drug: W‐RENA (Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: W‐RENA (Internet-based maintenance treatment)
Study: 17085994
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg tid PO
Study: 15485403
Drug: Placebo-based conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-based conventional antihypertensive therapy
Study: 11487451
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (conjugated estrogen with progestin)
Study: 8204123
Drug: Accelerated tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated tissue plasminogen activator (t-PA) and intravenous heparin
Study: 8204123
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of streptokinase plus t-PA with intravenous heparin
Study: 8204123
Drug: Combination strategy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination strategy
Study: 3732715
Drug: Diltiazem (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (360 mg daily)
Study: 29669938
Drug: Canagliflozin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (300 mg/d)
Study: 10774784
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment alone (matched controls with high cholesterol)
Study: 10774784
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment alone (matched controls with normal cholesterol)
Study: 1736002
Drug: Perfusion flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion flow rate at 1.75 L.min‐1.m‐2
Study: 1736002
Drug: Perfusion flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion flow rate at 2.25 L.min‐1.m‐2
Study: 30730957
Drug: TXA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA treatment
Study: 30282686
Drug: Waiting-list group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list group (standard acupuncture treatment after the study)
Study: 27100101
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 supplementation (90 μg) and cholecalciferol (10 μg)
Study: 27100101
Drug: Cholecalciferol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (10 μg) alone
Study: 25285539
Drug: Atazanavir, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d
Study: 25285539
Drug: Raltegravir, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir, 400 mg twice daily
Study: 25285539
Drug: Darunavir, 800
Normalized name: Darunavir, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir, 800 mg/d, with ritonavir, 100 mg/d
Study: 22918156
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily for 24 weeks
Study: 17388711
Drug: Galantamine (8-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8-24 mg)
Study: 7549379
Drug: Astragalus membranaceus
Normalized name: Astragalus membranaceus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus membranaceus (AM) oral liquor combined with routine therapy
Study: 26995369
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels <3 ng/L
Study: 26995369
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels 3-14 ng/L
Study: 26995369
Drug: hs-cTnT levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT levels ≥14 ng/L
Study: 24033567
Drug: Walnut supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut supplement diet (75 g per day)
Study: 22061077
Drug: Prucalopride (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (2-4 mg daily)
Study: 15548969
Drug: Cyclosporine withdrawal
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine withdrawal after 3 months of treatment with sirolimus
Study: 15548969
Drug: Cyclosporine continued
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine continued after 3 months of treatment with sirolimus
Study: 11578152
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily)
Study: 29729555
Drug: Psychoeducation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation and Supportive Therapy (PST)
Study: 25303337
Drug: Liberal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal paracetamol use
Study: 25303337
Drug: Restricted paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted paracetamol use
Study: 10438389
Drug: Intranasal mupirocin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mupirocin, twice daily for 5 days
Study: 7551950
Drug: Cisplatin given
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin given daily with radiotherapy
Study: 2350528
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg alone
Study: 31762342
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) based pain education
Study: 24293225
Drug: R&R2MHP cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: R&R2MHP cognitive skills program (group treatment)
Study: 24092567
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 μg) + Formoterol (6 μg) on demand
Study: 24092567
Drug: Regular Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Regular Budesonide (400 μg) on demand
Study: 24092567
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg) on demand
Study: 11788109
Drug: Transvaginal natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal natural progesterone gel (4% or 8%) applied every other day for six doses per month
Study: 19181970
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg infusion)
Study: 11600554
Drug: L-thyroxine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine (mean dose, 85.5 +/‐ 4.3 microg/d)
Study: 10175988
Drug: Prolonged prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged prophylaxis with enoxaparin (low-molecular-weight heparin) administered during hospitalization and for 3 weeks after discharge
Study: 10175988
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term prophylaxis administered only during hospitalization
Study: 31752604
Drug: Strategy-based Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategy-based Training to Enhance Memory (STEM) - 8-session treatment protocol incorporating self-generation, spaced learning, and retrieval practice.
Study: 29668397
Drug: LED treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED treatment at 2.4 J/cm2 (wavelengths 625, 660, 850 nm) three times a week for 8 weeks
Study: 25081363
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml foam (22 kcal) consumed immediately after main meals (M)
Study: 25081363
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml foam (22 kcal) consumed after snacks (S)
Study: 25081363
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml foam (22 kcal) consumed in-between snacks and main meals (I)
Study: 9074306
Drug: Moclobemide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (mean dose 440 mg +/- 123 mg)
Study: 9074306
Drug: Fluoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (mean dose 35 mg +/- 8 mg)
Study: 9074306
Drug: Fluoxetine (Control)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Control)
Study: 3021407
Drug: High-carbohydrate, guar
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate, guar gum fiber (HCF) bars (35.7 g carbohydrate and 6.6 g guar gum/bar)
Study: 27496046
Drug: Cognitive Patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Patient Education in combination with active individualized physiotherapy (COPE-PT)
Study: 23716067
Drug: MTX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX plus hydroxychloroquine plus sulfasalazine plus low-dose prednisone (arm 1)
Study: 23716067
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with MTX and prednisone
Study: 19926503
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection into the superior joint space (SJS)
Study: 19926503
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injections to the SJS and the pericapsular tissues (PT)
Study: 18539084
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (constant medication)
Study: 10993127
Drug: Fluvoxamine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50-100 mg/day)
Study: 8959316
Drug: Regular NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular NSAID use (at least twice weekly for 12 months or longer)
Study: 1388048
Drug: Fadrozole 1
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 1 mg orally per day
Study: 1388048
Drug: Fadrozole 4
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole 4 mg orally per day
Study: 1388048
Drug: Fadrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole (1 or 4 mg)
Study: 27322481
Drug: AERAS-422 high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AERAS-422 high dose (>10(6)‐<10(7)CFU)
Study: 27322481
Drug: AERAS-422 low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AERAS-422 low dose (>10(5)‐<10(6)CFU)
Study: 22834768
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks treatment with vaginal progesterone
Study: 12118018
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic radiotherapy (TRT)
Study: 12118018
Drug: Sequential thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential thoracic radiotherapy (TRT)
Study: 7851354
Drug: Intrathecal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal infusion with a bolus dose of 100 micrograms morphine followed by a 24 h infusion of 200 micrograms morphine (8.3 micrograms h‐1)
Study: 7851354
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion with a bolus dose of 2 mg of morphine followed by a 24 h infusion of morphine 200 micrograms h‐1 + 0.25% bupivacaine 4 ml h‐1
Study: 2895963
Drug: HOE 760
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 760 (histamine H2-receptor antagonist)
Study: 25418493
Drug: Ezetimibe 20
Normalized name: atorvastatin-ezetimibe 20 mg-10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 20 mg/d
Study: 21645424
Drug: Self‐administered, semiquantitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered, semiquantitative food frequency questionnaire (FFQ)
Study: 16774480
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) - 24-hour intravenous infusion
Study: 15322436
Drug: CEI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI of 0.5% bupivacaine plus IEB of 0.5% bupivacaine 4 times daily (n = 29)
Study: 15322436
Drug: IEB of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: IEB of normal saline plus IEB of 0.5% bupivacaine 4 times daily (n = 27)
Study: 11771598
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (TCI) of propofol (3 to 8 microg/ml)
Study: 11771598
Drug: Manually Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually Controlled Infusion (MCI) of propofol (approximately 2 mg/kg bolus and 3 to 10 mg/kg/h infusion)
Study: 11771598
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (TCI) of propofol
Study: 11771598
Drug: Manually Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually Controlled Infusion (MCI) of propofol
Study: 8499957
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral conjugated equine estrogens, 0.625 mg daily, with sequential oral dl‐norgestrel, 0.15 mg daily, for 12 days per month
Study: 8499957
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estradiol‐17 beta, 0.05 mg daily, with sequential transdermal norethindrone acetate, 0.25 mg daily, for 14 days per month
Study: 25257871
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 15 mg of terbutaline (TER)
Study: 22486552
Drug: Pantoprazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole treatment for up to 16 weeks
Study: 22486552
Drug: Observational phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observational phase after pantoprazole treatment
Study: 17094978
Drug: Mifepristone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (25 mg, two pills every 14 days during DMPA therapy)
Study: 17094978
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two pills every 14 days during DMPA therapy)
Study: 17848882
Drug: 0.25 mL
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mL Epaxal
Study: 17848882
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL Epaxal
Study: 17848882
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection site pain
Study: 9010709
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.05 mg.kg-1)
Study: 6529913
Drug: Trazodone (223
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (223 mg daily)
Study: 6529913
Drug: Amitriptyline (95.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (95.3 mg daily)
Study: 21939467
Drug: DBS +
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DBS + Optimal Drug Therapy (ODT)
Study: 9036412
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment according to the protocol of the German AML‐Cooperative Group (Münster, FRG)
Study: 9036412
Drug: Antileukemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antileukemic therapy
Study: 4043711
Drug: 9-deoxy-16, 16-dimethyl-9-methylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-deoxy-16, 16-dimethyl-9-methylene prostaglandin E2 (vaginal suppository)
Study: 24170677
Drug: Chronic anthocyanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic anthocyanin consumption (500 mg/day)
Study: 22771848
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg daily for 8 weeks
Study: 17387192
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil (0.3 mg x kg(‐1), every 3 hours for 24‐48 hours)
Study: 16261199
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon alpha‐2b for nasal spray
Study: 29117180
Drug: Residual insecticide
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual insecticide treatment (RIT)
Study: 25625810
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (F/V+, Sed- first, then PA+)
Study: 16844891
Drug: Medication-randomized clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-randomized clinical trial scenario
Study: 10831902
Drug: Immunotoxin MDX‐RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotoxin MDX‐RA (low dose: 50 units)
Study: 10831902
Drug: Immunotoxin MDX‐RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotoxin MDX‐RA (high dose: 100 units)
Study: 7894066
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of hypertension therapy
Study: 3128589
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium by MDI (1 mg per actuation)
Study: 22002175
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 or 200 mg/day)
Study: 19224159
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus intravenous supplementation with omega‐3 fish oil emulsion 0.2 g/kg every day (FO group)
Study: 19224159
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus intravenous supplementation with omega‐3 fish oil emulsion (FO group)
Study: 12149668
Drug: Lercanidipine tablets
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine tablets 10 mg once-daily (n = 234)
Study: 12149668
Drug: Losartan tablets
Normalized name: losartan Oral Tablet
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan tablets 50 mg once-daily (n = 231)
Study: 9862408
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray and nicotine gum
Study: 320856
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (1,600 I.U. of d-alpha-tocopherol succinate daily) for 6 months
Study: 16707911
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy for 6 months
Study: 7030221
Drug: Aero-chamber with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aero-chamber with fenoterol (beta 2 stimulant)
Study: 22093205
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose eptifibatide (1 μg/kg/min; eCrCl <50 ml/min)
Study: 22093205
Drug: Excess dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excess dose eptifibatide (2 μg/kg/min; eCrCl <50 ml/min)
Study: 22093205
Drug: Early provisional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early provisional treatment
Study: 22093205
Drug: Delayed provisional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed provisional treatment
Study: 17588225
Drug: Hydrocortisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (30 mg p.o.) with reboxetine (4 mg p.o.)
Study: 10103294
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of stimulant medication
Study: 7788958
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg or 500 mg b.i.d.
Study: 7788958
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg or 500 mg t.i.d.
Study: 1979797
Drug: Antihistamines (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines (specific type not mentioned)
Study: 417365
Drug: Baclofen (20‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20‐120 mg daily)
Study: 31669329
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment (7 monthly injections)
Study: 31389581
Drug: B-ultrasound-guided puncture
Normalized name: MAGNI-GUIDE (B-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-ultrasound-guided puncture treatment
Study: 26068865
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN)
Study: 26068865
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin (BBI)
Study: 24368463
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy plus amitriptyline
Study: 19427159
Drug: Morphine+Magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine+Magnesium
Study: 12414003
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 2% plain lignocaine
Study: 12414003
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 0.9% sodium chloride solution (placebo)